Inside Biotech: TGA raises a red flag on GLP-1 drugs — but uncertainty remains

The booming weight-loss drug market felt a jolt in Australia on Tuesday, when the Therapeutic Goods Administration issued a safety alert warning of potential links between GLP-1 receptor agonists (GLP-1 RAs) and suicidal thoughts or behaviours. The update — affecting widely used medicines for type 2 diabetes and obesity — arrives amid mounting scrutiny of this high-profile class of therapies. What’s changed According to the TGA’s update, product labelling for all GLP-1 RAs marketed in Australia — including ...